Issue Date: March 20, 2017
Allergan, Editas form eye drug alliance
Allergan and Editas Medicine have established an ophthalmic-disease-related R&D alliance. Allergan will pay $90 million up front to access up to five early-stage CRISPR genome-editing programs at Editas. Included is Editas’s lead program for Leber congenital amaurosis, a rare, inherited retinal degenerative disease. Allergan will be responsible for developing and commercializing any resulting products. Editas could codevelop up to two.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society